ES2394349B1 - Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar - Google Patents

Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar Download PDF

Info

Publication number
ES2394349B1
ES2394349B1 ES201231343A ES201231343A ES2394349B1 ES 2394349 B1 ES2394349 B1 ES 2394349B1 ES 201231343 A ES201231343 A ES 201231343A ES 201231343 A ES201231343 A ES 201231343A ES 2394349 B1 ES2394349 B1 ES 2394349B1
Authority
ES
Spain
Prior art keywords
beta
page
pulmonary
application
issn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES201231343A
Other languages
English (en)
Spanish (es)
Other versions
ES2394349A1 (es
ES2394349A8 (es
Inventor
Borja IBÁÑEZ CABEZA
Ana GARCÍA-ÁLVAREZ
Valentín FUSTER CARULLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital Clínic de Barcelona
Spanish National Centre for Cardiovascular Research
Original Assignee
Hospital Clínic de Barcelona
Spanish National Centre for Cardiovascular Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201231343A priority Critical patent/ES2394349B1/es
Application filed by Hospital Clínic de Barcelona, Spanish National Centre for Cardiovascular Research filed Critical Hospital Clínic de Barcelona
Publication of ES2394349A1 publication Critical patent/ES2394349A1/es
Publication of ES2394349A8 publication Critical patent/ES2394349A8/es
Priority to ES13785891T priority patent/ES2863749T3/es
Priority to PCT/ES2013/070611 priority patent/WO2014033343A1/es
Priority to EP13785891.6A priority patent/EP2891490B1/en
Priority to US14/424,861 priority patent/US10532038B2/en
Priority to JP2015529082A priority patent/JP6539206B2/ja
Priority to DK13785891.6T priority patent/DK2891490T3/da
Application granted granted Critical
Publication of ES2394349B1 publication Critical patent/ES2394349B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES201231343A 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar Withdrawn - After Issue ES2394349B1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES201231343A ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
ES13785891T ES2863749T3 (es) 2012-08-29 2013-08-28 Agonistas de adrenoreceptores beta-3 para el tratamiento de hipertensión pulmonar debida a cardiopatía izquierda
DK13785891.6T DK2891490T3 (da) 2012-08-29 2013-08-28 Beta-3 adrenoceptor-agonister til behandlingen af pulmonal hypertension på grund af sygdom i venstre side af hjertet
PCT/ES2013/070611 WO2014033343A1 (es) 2012-08-29 2013-08-28 Agonistas de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
EP13785891.6A EP2891490B1 (en) 2012-08-29 2013-08-28 Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension due to left heart disease
US14/424,861 US10532038B2 (en) 2012-08-29 2013-08-28 Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
JP2015529082A JP6539206B2 (ja) 2012-08-29 2013-08-28 肺高血圧症の治療のためのベータ−3アドレナリン受容体アゴニストの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231343A ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar

Publications (3)

Publication Number Publication Date
ES2394349A1 ES2394349A1 (es) 2013-01-30
ES2394349A8 ES2394349A8 (es) 2013-04-25
ES2394349B1 true ES2394349B1 (es) 2013-11-04

Family

ID=47520452

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201231343A Withdrawn - After Issue ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
ES13785891T Active ES2863749T3 (es) 2012-08-29 2013-08-28 Agonistas de adrenoreceptores beta-3 para el tratamiento de hipertensión pulmonar debida a cardiopatía izquierda

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13785891T Active ES2863749T3 (es) 2012-08-29 2013-08-28 Agonistas de adrenoreceptores beta-3 para el tratamiento de hipertensión pulmonar debida a cardiopatía izquierda

Country Status (6)

Country Link
US (1) US10532038B2 (cg-RX-API-DMAC7.html)
EP (1) EP2891490B1 (cg-RX-API-DMAC7.html)
JP (1) JP6539206B2 (cg-RX-API-DMAC7.html)
DK (1) DK2891490T3 (cg-RX-API-DMAC7.html)
ES (2) ES2394349B1 (cg-RX-API-DMAC7.html)
WO (1) WO2014033343A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
WO2022198259A1 (en) * 2021-03-25 2022-09-29 The Heart Research Institute Ltd Treatment methods for pulmonary arterial hypertension
EP4313019A4 (en) * 2021-03-31 2025-02-12 B3AR Therapeutics, Inc. Compositions of micronized solabegron and methods of use
IT202300021417A1 (it) 2023-10-13 2025-04-13 Univ Pisa Agonisti o attivatori del recettore adrenergico beta-3

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4338333A (en) 1979-06-16 1982-07-06 Beecham Group Limited Ethanamine derivatives their preparation and use in pharmaceutical compositions
ATE1899T1 (de) 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
PT82120B (en) 1985-03-01 1988-06-16 Beecham Group Plc Process for preparing veterinary formulations containing ethanolamine derivatives
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
IT1204416B (it) 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
ATE144139T1 (de) 1989-06-13 1996-11-15 Sanofi Sa Verwendung von phenylethanolaminen zur herstellung von medikamenten gegen augenleiden
GB8925032D0 (en) 1989-11-06 1989-12-28 Ici Plc Chemical compounds
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
ATE185564T1 (de) 1992-08-31 1999-10-15 Sankyo Co Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
NO303782B1 (no) 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
JP3100165B2 (ja) 1994-11-29 2000-10-16 大日本製薬株式会社 インドール誘導体
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ES2158996T3 (es) 1995-09-21 2001-09-16 Lilly Co Eli Agonistas beta3 adrenergicos selectivos.
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
CZ126598A3 (cs) 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
WO1997025311A1 (en) 1996-01-10 1997-07-17 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下3▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
IL131130A0 (en) 1997-01-28 2001-01-28 Merck & Co Inc Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
AU735249B2 (en) 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
HUP0301329A2 (hu) 2000-07-13 2003-08-28 Eli Lilly And Co. Béta3 Adrenergiás agonisták, valamint ezen vegyületeket tartalmazó gyógyászati készítmények és eljárás e vegyületek előállítására
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US20040242485A1 (en) 2003-05-30 2004-12-02 Takashi Kadowaki Compositions and methods for the amelioration of leptin resistance
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
CN102764438A (zh) 2012-01-30 2012-11-07 林曙光 β3肾上腺素受体激动剂的新用途

Also Published As

Publication number Publication date
US10532038B2 (en) 2020-01-14
EP2891490B1 (en) 2020-12-09
JP2015526497A (ja) 2015-09-10
EP2891490A1 (en) 2015-07-08
ES2863749T3 (es) 2021-10-11
ES2394349A1 (es) 2013-01-30
DK2891490T3 (da) 2021-03-15
WO2014033343A1 (es) 2014-03-06
WO2014033343A9 (es) 2014-04-24
US20150374655A1 (en) 2015-12-31
JP6539206B2 (ja) 2019-07-03
ES2394349A8 (es) 2013-04-25

Similar Documents

Publication Publication Date Title
RU2673081C1 (ru) Сочетанные препараты неосакситоксина для пролонгированной местной анестезии
ES2749096T3 (es) Terapias de combinación para el tratamiento de la enfermedad de Alzheimery transtornos relacionados
AU2018250214B2 (en) Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
US20190134036A1 (en) Topical formulations of pde-4 inhibitors and their methods of use
CN109715151A (zh) 用于治疗癫痫性紊乱的方法和组合物
Van der Schueren et al. Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model
PT1112075E (pt) Composições para o tratamento da disfunção eréctil masculina
CN112166111A (zh) 治疗纤维化疾病的方法
JP2017132802A (ja) ヒストンアセチルトランスフェラーゼ活性剤の使用
ES2394349A1 (es) Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
JP2014521694A (ja) 安定な注射用抗炎症性溶液
TW200303214A (en) Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
ES2858551T3 (es) Antagonistas del receptor de tromboxano
WO2024006841A2 (en) Compositions for weight loss and cancer treatment
KR20070036740A (ko) 통증 완화 방법
ES2278930T3 (es) Uso de un derivado de la piridazinona en el tratamiento de una insuficiencia cardiaca congestiva.
US9629827B2 (en) Methods of treating vasodilatory shock
EP3607948A1 (en) Tissue transglutaminase modulators for medicinal use
US20110034504A1 (en) Agent for preventing and/or treating vascular diseases
ZA200507497B (en) Therapeutic and/or preventive agent for chronic skin disease
SK282353B6 (sk) Farmaceutický prostriedok na intravenózne podanie
Moriyama et al. Effects of a novel benzodiazepine derivative, JM-1232 (-), on human gastroepiploic artery in vitro
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
Ferreira Cardiovascular activity of a new phenylpiperazine derivative of arylurethane
KR20190017801A (ko) 티몰롤을 포함하는 조성물 및 국소 투여에 의한 주사의 치료에 있어서의 이들의 용도

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2394349

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20131104

FA2A Application withdrawn

Effective date: 20140318